PHARMACOKINETICS, PHARMACODYNAMICS, LONG-TERM EFFICACY AND SAFETY OF ORAL 1-DEAMINO-8-D-ARGININE VASOPRESSIN IN ADULT PATIENTS WITH CENTRALDIABETES-INSIPIDUS
Ksl. Lam et al., PHARMACOKINETICS, PHARMACODYNAMICS, LONG-TERM EFFICACY AND SAFETY OF ORAL 1-DEAMINO-8-D-ARGININE VASOPRESSIN IN ADULT PATIENTS WITH CENTRALDIABETES-INSIPIDUS, British journal of clinical pharmacology, 42(3), 1996, pp. 379-385
1 The pharmacokinetics and pharmacodynamics of intranasal (IN) and ora
l 1-deamino-8-D-arginine vasopressin (DDAVP) were compared in 10 Chine
se adults with central diabetes insipidus previously controlled on IN
DDAVP. This was followed by comparison of the acute pharmacodynamics o
f commonly used oral preparations (containing 100, 200 and 400 mu g pe
r tablet) and a 1 year prospective evaluation of the long-term safety
and efficacy of oral DDAVP. 2 Following 20 mu g IN and 200 mu g orally
, respective plasma DDAVP concentrations peaked after 45.6 +/- 7.3 and
93.3 +/- 3.3 (mean +/- s.e.mean) min, reaching 24.1 +/- 4.7 and 15.1
+/- 3.2 pmol 1(-1) and respective terminal half-lives were 2.2 +/- 0.1
and 2.0 +/- 0.1 h. Based on the area under the concentration-time-cur
ve, the bioequivalent IN/oral ratio was 1:16. 3 As judged by changes i
n urine flow rate and osmolality after IN or oral (100, 200 or 400 mu
g) DDAVP, antidiuretic activity increased rapidly during the second ho
ur and peaked at 4 h. The antidiuresis duration and magnitude correlat
ed with the oral dose (P < 0.001 and < 0.05 respectively), and was lea
st following 100 mu g (P < 0.01 vs 200 or 400 mu g). Increasing the do
se from 200 to 400 mu g did not increase maximal antidiuretic activity
significantly, but there was a trend towards a longer duration of act
ion (P = 0.076). 4 During the 1-year prospective study with oral DDAVP
300-600 mu g per day in two to three doses, stable and satisfactory a
ntidiuresis (comparable with that on previous IN therapy) was maintain
ed; tablets were well-tolerated and no side-effect warranted drug with
drawal. 5 These findings suggest that the 100 and 200 mu g preparation
s of oral DDAVP are adequate for the long-term control of central diab
etes insipidus in our population, and that the 400 mu g preparation ma
y have a role if the frequency of administration is to be reduced.